NRSN NeuroSense Therapeutics
- 1.230
- -0.030-2.38%
- 1.280
- +0.050+4.07%
NeuroSense Therapeutics News
Express News | Neurosense Therapeutics: Study Expected to Reveal Safety of Primec in Ad, and Shed Light on Efficacy, Biological Activity of Combination Therapy
Express News | NeuroSense Shares Are Trading Higher After the Company Announced an Alzheimer's Drug Development Collaboration With Genetika+
Express News | Neurosense and Genetika+ Initiate Precision Medicine Collaboration Beginning With Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
Express News | Neurosense Presents Positive Data Validating Phase 2B Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Express News | NeuroSense To Present PARADIGM Data At American Academy Of Neurology Annual Meeting
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces...
Reported Earlier, NeuroSense Therapeutics Prices $4.5M Registered Direct Offering Of 2.98M Shares And Concurrent Private Placement
NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseas
NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration fieldLonza to develop, optimize, and qualify a method utili
NeuroSense Therapeutics GAAP EPS of -$0.83 Misses by $0.01
Express News | NeuroSense Therapeutics Q4 EPS $(0.16) Beats $(0.23) Estimate
XXII, GRIN and XTIA Are Among Mid-day Movers
NeuroSense Therapeutics Had Cash of $2.6M at Dec 31 >NRSN
NeuroSense Therapeutics Had Cash of $2.6M at Dec 31 >NRSN
Express News | NeuroSense FY23 EPS $(0.83) Beats $(0.85) Estimate
Press Release: NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update.
NeuroSense Reports Additional Positive Results From Its ALS Phase 2b PARADIGM Trial
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reports...
Express News | NeuroSense Regains Nasdaq Compliance
NeuroSense Regains Compliance With NASDAQ Minimum Bid Price Rule
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced...
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
NeuroSense Reviews 2023 Achievements; Provides Road Map For 2024
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussionsStatistically Signif
Analysis
Price Target
No Data
